Business Context and Reporting Period
This Form 8-K, filed on September 18, 2026, by Iridium Communications Inc. (IRDM), addresses a special meeting of stockholders scheduled for September 24, 2026. The meeting concerns the proposed acquisition of Iridium by Rocket Lab Corporation (Rocket Lab) under a Merger Agreement dated June 28, 2026. The transaction involves a two-step merger process, with closing expected in mid-2027, subject to stockholder approval and other conditions.
Key Financial Metrics and Valuation Data
The filing provides supplemental financial data used in Evercore's valuation analyses as of June 30, 2026:
- Merger Consideration: $54.00 per share of Iridium Common Stock.
- Iridium Estimated Net Debt: Approximately $2,102 million.
- Iridium LTM Adjusted OEBITDA: Approximately $527 million.
- Iridium Fully Diluted Shares: Approximately 110.5 million.
- Iridium Tax Benefits: Present value of net operating losses and R&D tax credits estimated at $244 million.
- Rocket Lab Fully Diluted Shares: Approximately 662.3 million.
- Stock Prices (June 26, 2026): Iridium closed at $43.52; Rocket Lab closed at $84.54.
Material Changes and Supplemental Disclosures
This filing amends the definitive proxy statement to address disclosure deficiencies alleged in three pending lawsuits and demand letters from stockholders. The amendments clarify valuation methodologies and inputs:
- Precedent Transactions Analysis: Evercore applied a TEV/LTM Adjusted EBITDA multiple range of 10.0x to 14.0x, implying an equity value range of $28.69 to $47.77 per share for Iridium.
- Discounted Cash Flow (DCF) Analysis: Utilized a WACC range of 9.0% to 10.0% and terminal growth rates of 2.5% to 3.5%, implying an equity value range of $29.97 to $45.54 per share for Iridium.
- Analyst Price Targets: Updated ranges for Iridium ($16.00 to $60.00 as of June 26, 2026) and Rocket Lab ($60.00 to $150.00 as of June 26, 2026).
- Rocket Lab Valuation: Supplemental data indicates implied equity values for Rocket Lab ranging from $61.22 to $99.03 based on 2027 revenue estimates, and $46.23 to $102.45 based on future share price analysis.
Outlook, Risks, and Contingencies
Management Commentary: Iridium management asserts that the claims in the pending litigation are without merit and that the original proxy statement complied with applicable laws. However, to avoid delay and distraction, the company voluntarily supplemented the disclosures.
Litigation Risks: Three lawsuits have been filed in the Supreme Court of the State of New York seeking to enjoin the merger and demanding additional disclosures. The company anticipates potential additional complaints or demand letters.
Transaction Risks: The filing highlights standard forward-looking risks, including the failure to obtain regulatory or stockholder approvals, the receipt of unsolicited third-party proposals, integration challenges, and the inability to realize anticipated synergies or tax benefits.
Investor Verification Checklist
- Verify the status of the three pending lawsuits in New York State Supreme Court and any potential injunctions.
- Confirm the final vote results of the Special Meeting scheduled for September 24, 2026.
- Review the definitive proxy statement (Schedule 14A) filed on August 26, 2026, for the complete Merger Agreement terms.
- Monitor regulatory approval progress required for the mid-2027 closing timeline.
- Assess the accuracy of the $2,102 million net debt figure and the $527 million LTM Adjusted OEBITDA in Iridium's most recent financial filings.